Clinical Research Directory

Inclusion Criteria: * 1\. The patient must be willing to sign the informed consent form. * 2\. Age ≥18 years and ≤75 years. * 3\. Metastatic or recurrent solid tumors with confirmed HPV18 infection based on TNM \& FIGO staged histopathological investigation. . * 4\. Subjects who have failed anti-tumor treatment in the past and lack effective treatment options. * 5\. HPV18 positive and HLA-DRB1\*0901 allele. * 6\. ECOG performance status ≤1. * 7\. Estimated life expectancy ≥ 3 months. * 8\. Patients must have at least one measurable lesion defined by RECIST 1.1. * 9\. Patients with any organ dysfunction as defined below: 1. Leukocytes≥3.0 x 10\^9/L; 2. blood platelets ≥75 x 10\^9/L; 3. hemoglobin≥85g/L; 4. Absolute lymphocyte count≥0.8 x 10\^9/L 5. Serum albumin ≥ 30g/L; 6. total bilirubin≤1.5×ULN; ALT/AST≤3×ULN or ≤5×ULN for liver metastases; 7. Creatinine clearance ≥50mL/min; or serum creatinine ≤1.5×ULN; 8. INR≤1.5×ULN; APTT≤1.5×ULN; 9. LVEF≥50%; 10. SpO2≥92%. * 10\. Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 1 year after receiving HRYZ-T101 cell transfusion treatment. HCG test for female with potential fertility must be negative within 7 days before apheresis. Exclusion Criteria: * 1\. Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it is known that any ingredient used in the treatment of this study will produce allergic reactions. * 2\. Those who have undergone systemic anti-tumor treatment within 4 weeks before apheresis, including who have received conventional chemotherapy, large-area radiotherapy, targeted therapy, immunotherapy or biological therapy, and other anti-tumor treatment. Have received small molecule targeted drugs and oral fluorouracils or Chinese herbal medicine within 2 weeks before apheresis. * 3\. Have received any investigational drug within 4 weeks before apheresis, or have participated in another clinical study at the same time. * 4\. Have received any cell therapy products before. * 5\. Those who have undergone major surgery within 4 weeks before apheresis, or minor surgery within 2 weeks before apheresis. * 6\. Toxicity of previous treatment has not been mitigated or ≤ Grade 1 before apheresis. * 7\. Have received live attenuated vaccine or adenovirus vector vaccine within 4 weeks before apheresis. * 8\. Have central nervous system metastasis with symptoms. * 9\. Subjects with clinical cardiac symptoms or diseases that cannot be well controlled. * 10\. Subjects with serious or uncontrolled systemic disease or any unstable systemic disease. * 11\. Subjects with active infection requiring systemic treatment with anti-infective drugs within 2 weeks before apheresis. * 12\. Subjects have any active autoimmune disease or history of autoimmune disease. * 13\. Have received immunosuppressive agents, or systemic corticosteroids, immunomodulators within 2 weeks before apheresis. * 14\. Subjects with other malignant tumors. Except for: (1) Carcinoma in situ with curative treatment and no evidence of recurrence for at least 2 years; (2) the primary malignant tumor has been completely resected and achieved CR for ≥ 2 years. * 15\. Subjects with history of thromboembolism ≥ Grade 3 within 6 months before apheresis, or is receiving thrombolytic or anticoagulant for high-risk of thromboembolism. * 16\. Known HIV or syphilis infection, and/or active hepatitis B virus or hepatitis C virus infection. * 17\. Organ transplanters and allogeneic cell transplanters. * 18\. Subjects with active pulmonary tuberculosis infection within 1 year or have not received treatment at least 1 year before apheresis. * 19\. Pregnant or lactating female, or those whose HCG test is positive before enrollment. * 20\. According to the judgment of the researcher, those who are not suitable for the group, such as poor compliance.